#USA #Irvine #B-cell Lymphoma #PeproMene Bio #PMB-CT01

PeproMene Bio Achieves Significant Milestones in Lymphoma Treatment

PeproMene Bio, Inc., a clinical-stage biotechnology firm based in Irvine, California, has made headlines with its recent publication in The Lancet, one of the globe's most renowned medical journals. Their Phase 1 clinical trial has showcased groundbreaking results for patients suffering from relapsed or refractory B-cell lymphomas, especially those who have previously undergone CAR-T therapy targeting CD19.

Breakthrough Clinical Outcomes

The study focused on their innovative treatment, PMB-CT01, a CAR-T cell therapy that specifically targets the BAFF-R (B-cell activating factor receptor). This novel therapy demonstrated remarkable efficacy, with complete responses observed in 80% of patients treated, including four out of six individuals whose cancers advanced post conventional CAR-T treatment. The lack of relapses and some responses lasting up to 35 months indicate a possibly curative option for these patients.

Dr. Larry W. Kwak, the scientific founder of PeproMene Bio, described the impact of their findings, noting the absence of recurrences as a significant milestone in cancer treatment. He emphasized that the success of PMB-CT01 may not only revolutionize CAR-T therapies for blood cancers but might also enhance outpatient treatment accessibility for underprivileged patients.

Safety Profile and Patient Expansion

A notable aspect of the PMB-CT01 treatment is its favorable safety profile. Instances of cytokine release syndrome and immune effector cell-associated neurotoxicity were limited to grade 1, showcasing a well-tolerated treatment model. Following the promising results of the initial testing site at City of Hope, the trial has now expanded to multiple clinical centers across the United States, allowing more patients to access this revolutionary treatment.

Future Perspectives and Support from IFLI

PeproMene Bio's strides have not gone unnoticed, with the Institute for Follicular Lymphoma Innovation (IFLI) pledging up to $11 million to support the ongoing clinical development of PMB-CT01 in recurrent or refractory follicular lymphoma patients. Dr. Mehrdad Mobasher, an executive associate at IFLI, expressed enthusiasm for the new therapeutic prospects that this collaboration can yield against hard-to-treat lymphomas.

Conclusion

The publication of the PMB-CT01 study in The Lancet represents a pivotal moment in the landscape of lymphoma treatment. As the research unfolds, it opens new avenues for patients who have limited options, reinforcing PeproMene Bio’s commitment to innovation in the field of immunotherapy. Their continued efforts to harness the potential of CAR-T therapies highlight a proactive approach in addressing the challenges of relapsed or refractory lymphomas, making significant strides toward more effective cancer care. Stay tuned as PeproMene Bio continues to shape the future of cancer treatment.